ALKBH5 and cancer: Inhibitors of ALKBH5/FTO and targeted deletion of METTL3/14 have been shown to enhance the effects of PD-L1 inhibitor immunotherapy by enhancing the expression of immune checkpoints and secretion of cytokines.112118121 In addition, RNA-modified regulators hold promise for development as biological indicators of cancer prognosis and response to immune checkpoint blockade.